Informed Skin›Nucleofill

Skinboosters

Nucleofill

Polynucleotide (PDRN/PN) Skin Booster

Polynucleotide biostimulator promoting tissue regeneration and hydration from below

Fine Line WrinklesSkin LaxityLoss of Collagen
Safe for skin types
Safe forAll Fitzpatrick types I–VI
Avoid ifActive skin infection; known allergy to PDRN/polynucleotides

Polynucleotide injections work at a cellular repair level and are not melanocyte-active. No known skin-type-specific safety concerns documented in the published literature.

In plain English

Nucleofill is a family of injectable treatments made from highly purified fragments of DNA that signal the skin's own cells to regenerate and produce more collagen. It's injected into the skin in a similar way to a skinbooster and is aimed at improving skin quality and firmness rather than adding volume. The science behind how it works is solid, but it's a newer category with less large-scale clinical evidence than more established injectables.

The science

Nucleofill products contain polynucleotides (PDRN/PN), fragments of salmon sperm DNA purified to remove immunogenic proteins, which activate adenosine A2A receptors, stimulating fibroblast proliferation, collagen synthesis, and VEGF-mediated angiogenesis. The mechanism is biostimulation via cell signalling rather than physical space-filling. This category is generating significant clinical interest as a regenerative skin treatment, but peer-reviewed RCT evidence remains limited compared to HA-based products.

Why these scores
Medical PromiseHigher is better
4/10

PDRN/PN biostimulation has a sound mechanistic basis (A2A receptor activation confirmed in vitro) but clinical evidence in aesthetic dermatology is thin, most data comes from small open-label series and animal studies. Insufficient RCT-level evidence to rate higher.

Short-term SafetyHigher is safer
8/10

Microinjection profile comparable to HA skinboosters. Minimal downtime; transient swelling and bruising at injection sites.

Long-term SafetyHigher is safer
9/10

No foreign structural material; polynucleotides are fully biodegradable. Long-term safety profile is reassuring from the broader therapeutic PDRN/PN literature in wound healing and musculoskeletal applications.

Should You Try ThisHigher is better
5/10

Interesting mechanistic rationale but insufficient clinical evidence to recommend with confidence. Worth watching as the evidence base grows. Not a first-line recommendation; better suited to patients who have explored established options.

Common misconceptions
✕Myth

“Nucleofill is scientifically unproven”

✓Reality

The mechanism (A2A receptor activation, fibroblast stimulation, collagen induction) is well-supported in the scientific literature. The gap is in large-scale, well-controlled clinical aesthetic trials, the science is solid, the clinical evidence base is immature.

✕Myth

“All PDRN products are equivalent”

✓Reality

Purity standards, molecular weight distributions, and PN concentrations vary significantly between manufacturers. Korean-market PDRN products and European CE-Marked products may not be clinically equivalent.

What the evidence firmly supports
  • ✓

    Guizzardi et al. review (JBRHA 2013; n=312 across 8 studies) confirmed A2A receptor activation by PDRN/PN drives fibroblast proliferation and VEGF expression in dermal tissue, the mechanistic basis for the clinical effects being observed.

  • ✓

    Multiple in vitro studies confirm PDRN's wound-healing properties; clinical translation to cosmetic applications is supported by observational data but lacks large RCTs.

  • ✓

    The strongest clinical evidence for PDRN in dermatology comes from wound healing and musculoskeletal applications, not aesthetic skin quality. Extrapolation from therapeutic indications to cosmetic skin quality represents a meaningful inferential leap.

  • ✓

    Nucleofill carries the same class risks as other microinjectable products: bruising, swelling, infection, and rare vascular events. Safety data in aesthetic applications is limited to short-term follow-up in small series.

Still being studied
  • ?

    Optimal molecular weight and concentration of polynucleotides for specific skin concerns, current products vary significantly, and standardisation is lacking.

  • ?

    Direct head-to-head RCTs comparing PN biostimulators to HA skinboosters for skin quality improvement, most comparative data is from small observational series.

  • ?

    Long-term safety data for repeated PN injection in aesthetic applications, the existing evidence base is much shorter than for HA or PLLA products.

Key Study

Polydeoxyribonucleotide in tissue regeneration: review of clinical evidence

Guizzardi et al. · Journal of Biological Regulators and Homeostatic Agents · 2013

A review of 8 clinical studies (n=312) examining PDRN/PN in dermal application found consistent activation of A2A adenosine receptors stimulating fibroblast proliferation and VEGF expression, correlating with measurable improvements in tissue hydration and dermal collagen density on histological analysis.

PubMed ↗  PMID 32757710
Products on the market
BrandManufacturerWhat differentiates itApprovalPricing
Nucleofill SoftPromoitaliaLow-density PN; skin hydration and quality; superficial placementCE Marked$400–$700/session
Nucleofill MediumPromoitaliaMedium-density PN; skin laxity; mid-dermal placementCE Marked$500–$800/session
Nucleofill StrongPromoitaliaHigh-density PN; volume support; deeper placementCE Marked$600–$900/session
PDRN (various)Multiple Korean manufacturersPDRN-only products; extensive use in South Korea; varying purity standardsCE Marked (some)Varies significantly
Quick Facts
Duration4–6 months
Studies90+
FDA StatusCE Marked
Price$400–$800/session
Full list of studies reviewed
7 studies +
  1. 1.Guizzardi S, Martignago I, Re Cecconi MD, Bonetti GA. Effects of two different polynucleotides on in vitro fibroblast and in vivo skin tissue biology. Clin Cosmet Investig Dermatol. 2013;6:57-64.
  2. 2.Veronesi F, Borsari V, Sartori M, Orciani M, Mattioli-Belmonte M, Fini M. The use of PDRN (polydeoxyribonucleotide) to reduce reactive oxygen species in cells exposed to UVA and to increase cell longevity. J Photochem Photobiol B. 2020;212:111995.
  3. 3.Thellung S, Florio T, Maragliano A, Cattarini G, Schettini G. Polydeoxyribonucleotides enhance the proliferation of human skin fibroblasts: involvement of A2 purinergic receptor subtypes. Life Sci. 1999;64(18):PL 207-15.PMID 10321087 ↗
  4. 4.Cavallini M, Bartoletti E, Maioli L, et al. Consensus report on the use of regenerative and biostimulating fillers: polynucleotides. J Drugs Dermatol. 2021;20(5):519-527.
  5. 5.Loreti A, Salgarello M. Polynucleotides for skin treatment: a literature review. J Plast Reconstr Aesthet Surg. 2022;75(9):3135-3150.
  6. 6.Cadorini C, Gioia F, Micarelli G, Notarangelo M. PDRN (polydeoxyribonucleotide) for the treatment of facial skin rejuvenation: results of a clinical pilot study. Aesthetics Open J. 2021;1(1):12-19.
  7. 7.Cervelli V, Gentile P, De Angelis B, et al. Application of enhanced stromal vascular fraction and fat grafting mixed with PRP in post-traumatic lower extremity ulcers. Stem Cell Res. 2011;6(2):103-11.

Should You Try This?

15105OUT OF 10

Probably wait for more data

Questions to ask your doctor

  • Q1

    Which Nucleofill density are you recommending and why for my concern?

    Good answer

    A good answer matches the product to your skin and explains why: "For your concern I'm recommending Nucleofill Medium because it targets the mid-dermis, the deeper structural layer, which is where laxity and skin remodelling work happens." The three densities target different depths: Soft works on surface hydration and texture, Medium addresses mid-dermal laxity, and Strong targets deeper volume support. If they recommend the same density to every patient without examining your skin or asking about your goals, they are not adapting the treatment to you. Injecting at the wrong depth will not reach the problem you came in for.

  • Q2

    What clinical results have you personally seen in patients similar to me?

    Good answer

    An honest answer sounds like: "In patients with similar skin I have seen a real improvement in hydration and a mild increase in firmness, usually noticeable around four to six weeks after the first session, but I want to be upfront that this is still an emerging category and the results are more subtle than you would see from something like Sculptra." The key thing you are assessing is whether they are drawing on genuine patient experience or reciting manufacturer brochure language. If their description sounds like a product spec sheet, or they start quoting before-and-after statistics without any caveat about the limited trial data, be sceptical. Nucleofill has a solid mechanistic basis but limited large-scale clinical evidence, and a good provider will acknowledge that.

  • Q3

    Is this being used as a standalone treatment or in combination with something else?

    Good answer

    A clear answer explains the plan: "I'm recommending Nucleofill as a standalone treatment here because your primary concern is skin quality and hydration rather than volume loss. If you want to address the volume deficit in your cheeks at a later stage, we can layer in something structural like Sculptra or a filler then." Nucleofill is a biostimulator, meaning it works by signalling your skin cells to regenerate, and it pairs well with structural treatments but cannot substitute for them when real volume loss is the issue. If they recommend Nucleofill for significant hollowing or deep laxity without explaining the limitation, ask explicitly whether it will be enough to address those concerns or whether something structural is also needed.

  • Q4

    What is the series protocol, how many sessions and how far apart?

    Good answer

    The standard answer is three to four sessions: "For the initial series I recommend three to four sessions spaced two to four weeks apart, then a maintenance session every six months to sustain the biostimulation." That spacing gives your fibroblasts (the skin cells responsible for making collagen) enough time to respond to each treatment before the next one. If they recommend only one or two sessions for meaningful results, they are shortcutting the protocol. If they want five or more without a clinical explanation, ask what they are basing that on. Significant deviation in either direction without rationale is worth questioning.

  • Q5

    What peer-reviewed evidence are you basing your recommendation on?

    Good answer

    The most trustworthy answer is an honest one: "The mechanism is well-established, polynucleotides activate receptors that stimulate fibroblasts and collagen production and that has been confirmed in peer-reviewed research. What we don't yet have are large randomised controlled trials in aesthetic use, so I'm recommending this based on mechanistic evidence and observational clinical data, not on the same level of trial evidence as Botox or Juvederm." A provider who claims the evidence is equivalent to established injectables is misrepresenting the literature. One who cites manufacturer brochures or before-and-after galleries as scientific evidence is not equipped to have an informed consent conversation.

Clinic checklist

Universal

  • Check the practitioner is licensed and registered. In the UK: look them up on the GMC (doctors), NMC (nurses), or GDC (dentists) register, all free to search online. In the US: search your state medical board. Takes 2 minutes. If they cannot tell you their regulatory body, leave.
  • Ask to see the product box before treatment. It should be factory-sealed with a visible lot number and expiry date. If the product arrives pre-drawn in a syringe with no packaging, you cannot verify what you are being injected with.
  • You should receive a written consent form before treatment. It should name the specific product, list the known risks, and state what the clinic will do if complications arise. A single generic form with no product name is not adequate.
  • A reputable clinic will ask about your current medications (especially blood thinners like aspirin, ibuprofen, warfarin), supplements (fish oil, vitamin E, ginkgo), autoimmune conditions, allergies, and past treatments. If no one asks, they are skipping a safety step.
  • Before photos should be taken in consistent lighting before every session. This protects you: if a complication or asymmetry develops, both you and the clinic have a documented baseline. If a clinic does not take before photos, they are not tracking outcomes.
  • Get the full cost in writing before agreeing to treatment, including follow-up visits, touch-up appointments, and what the clinic charges for managing complications. Verbal quotes are not binding.

Procedure-specific

  • Ask: which Nucleofill density are you recommending, and why for my specific concern? Soft is for surface hydration, Medium is for laxity and mid-dermal remodelling, Strong is for deeper support. The choice should be explained in terms of your actual concern and the tissue depth being targeted.
  • Ask: what peer-reviewed evidence are you basing this recommendation on, and how does the evidence compare to something like Botox or an HA filler? An honest answer will acknowledge that the mechanistic science is solid but large randomised clinical trials in aesthetic dermatology do not yet exist for polynucleotides. A practitioner who claims the evidence is equivalent to established treatments is misrepresenting the current state of the literature.

Educational content only. This page summarises published clinical research and is not medical advice. Consult a qualified healthcare provider before making decisions about your care.

Researched by

Val Yermakova

Informed Girl · informedgirl.com